Page 33 - Demo

CUAJ %u2022 APRIL 2025 %u2022 VOLUME 19, ISSUE 4 103Guideline: IC/BPS80. Cardenas-Trowers OO, Abraham AG, Dotson TK, et al. Bladder instillations with triamcinolone acetonide for interstitial cystitis-bladder pain syndrome: A randomized controlled trial. Obstet Gynecol 2021;137:810-9. https://doi.org/10.1097/AOG.000000000000434881. Bade JJ, Laseur M, Nieuwenburg A, et al. A placebo-controlled study of intravesical pentosanpolysulphate for the treatment of interstitial cystitis. Br J Urol 1997;79:168-71. https://doi.org/10.1046/j.1464-410X.1997.03384.x82. Davis EL, El Khoudary SR, Talbott EO, et al. Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: A randomized double-blind clinical trial. J Urol 2008;179:177-85. https://doi.org/10.1016/j.juro.2007.08.17083. Barbalias GA, Liatsikos EN, Athanasopoulos A, Nikiforidis G. Interstitial cystitis: Bladder training with intravesical oxybutynin. J Urol 2000;163:1818-22. https://doi.org/10.1016/S0022-5347(05)67551-984. Manning J, Dwyer P, Rosamilia A, et al. A multicentre, prospective, randomised, doubleblind study to measure the treatment effectiveness of abobotulinum A (AboBTXA) among women with refractory interstitial cystitis/bladder pain syndrome. Int Urogynecol J2014;25:593-9. https://doi.org/10.1007/s00192-013-2267-885. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int 2009;104:657-61. https://doi.org/10.1111/j.1464-410X.2009.08495.x86. Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment %u2013 A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn 2016;35:609-14. https://doi.org/10.1002/nau.2276087. Evans RJ, Overholt T, Colaco M, Walker SJ. Injection location does not impact botulinum toxin A efficacy in interstitial cystitis/bladder pain syndrome patients. Can J Urol2020;27:10125-9.88. Pinto RA, Costa D, Morgado A, et al. Intratrigonal OnabotulinumtoxinA improves bladder symptoms and quality of life in patients with bladder pain syndrome/interstitial cystitis: A pilot, single center, randomized, double-blind, placebo controlled trial. J Urol2018;199:998-1003. https://doi.org/10.1016/j.juro.2017.10.01889. Akiyama Y, Nomiya A, Niimi A, et al. Botulinum toxin type A injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response. Int J Urol 2015;22:835-41. https://doi.org/10.1111/iju.1283390. Kasyan G, Pushkar D. 822 randomized controlled trial for efficacy of botulinum toxin type a in treatment of patients suffering bladder pain syndrome/interstitial cystitis with Hunners%u2019 lesions preliminary results. J Urol 2012;187:e335-e6. https://doi.org/10.1016/j.juro.2012.02.91291. Lai HH, Pickersgill NA, Vetter JM. Hunner Lesion phenotype in interstitial cystitis/bladder pain syndrome: A systematic review and meta-analysis. J Urol 2020;204:518-23. https://doi.org/10.1097/JU.000000000000103192. Whitmore KE, Fall M, Sengiku A, et al. Hunner lesion versus non-Hunner lesion interstitial cystitis/bladder pain syndrome. Int J Urol 2019;26 Suppl 1:26-34. https://doi.org/10.1111/iju.1397193. Ko KJ, Cho WJ, Lee YS, et al. Comparison of the efficacy between transurethral coagulation and transurethral resection of hunner lesion in interstitial cystitis/bladder pain syndrome patients: A prospective randomized controlled trial. Eur Urol 2020;77:644-51. https://doi.org/10.1016/j.eururo.2020.01.00294. Funaro MG, King AN, Stern JNH, et al. Endoscopic injection of low dose triamcinolone: Asimple, minimally invasive, and effective therapy for interstitial cystitis with Hunner Lesions. Urology 2018;118:25-9. https://doi.org/10.1016/j.urology.2018.03.03795. Rittenberg L, Morrissey D, El-Khawand D, Whitmore K. Kenalog injection into Hunner%u2019s lesions as a treatment for interstitial cystitis/bladder pain syndrome. Curr Urol2017;10:154-6. https://doi.org/10.1159/00044717196. Pinto R, Lopes T, Costa D, et al. Ulcerative and nonulcerative forms of bladder pain syndrome/interstitial cystitis do not differ in symptom intensity or response to onabotulinum toxin A. Urology 2014;83:1030-4. https://doi.org/10.1016/j.urology.2014.01.01897. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology2000;47:119-25. https://doi.org/10.1016/S0162-3109(00)00192-298. Sairanen J, Tammela TL, Leppilahti M, et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: A randomized comparative study. J Urol2005;174:2235-8. https://doi.org/10.1097/01.ju.0000181808.45786.8499. Forrest JB, Payne CK, Erickson DR. Cyclosporine A for refractory interstitial cystitis/bladder pain syndrome: Experience of 3 tertiary centers. J Urol 2012;188:1186-91. https://doi.org/10.1016/j.juro.2012.06.023100. Vollstedt A, Tennyson L, Turner K, et al. Evidence for early cyclosporine treatment for Hunner Lesion interstitial cystitis. Female Pelvic Med Reconstr Surg 2022;28:e1-e5. https://doi.org/10.1097/SPV.0000000000001108CORRESPONDENCE: Dr. Chris Doiron, Department of Urology, Queen%u2019s University, Kingston, ON, Canada; chris.doiron@queensu.ca; Dr. Ashley Cox, Department of Urology, Dalhousie University, Halifax, NS, Canada; ashleycox@dal.caCUA's free digital library of educational programs - available on demand!You will find:cua.org/uropediaSlides DecksClinical ToolsSurgical VideosWebinar RecordingsPodcastsMeeting RecordingsClaim section 3 self-assessment credits by completing the quiz for each program!CMYCMMYCYCMYKUROpedia-AD-BackPage-March2023-print.pdf 1 2023-03-06 2:36 PM